---
layout: default
title: Actaea Cimicifuga Root Atropa Belladonna Bryonia A
parent: 僅模型預測 (L5)
nav_order: 145
evidence_level: L5
indication_count: 0
---

# Actaea Cimicifuga Root Atropa Belladonna Bryonia A
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Multi-Ingredient Homeopathic Complex: From Unknown Indication to Unpredicted New Indication

## One-Sentence Summary

This submission contains an 11-component multi-ingredient combination product (including Actaea cimicifuga, Atropa belladonna, Nitroglycerin, Nux vomica, and others), whose original indications and mechanism of action are currently uncharacterized.
The TxGNN model was **unable to generate any repurposing predictions** for this candidate, as the drug was not found in the DrugBank knowledge graph.
Without predicted indications, clinical trial evidence, or safety data, **this candidate cannot be evaluated at this time**.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Not available |
| Predicted New Indication | None (TxGNN returned no predictions) |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 — Model prediction not generated; no actual studies identified |
| US Market Status | Not marketed |
| Number of NDAs | 0 |
| Recommended Decision | **Hold** |

---

## Why is This Prediction Reasonable?

No TxGNN prediction was generated for this candidate. The primary reason is the absence of a DrugBank ID (`drugbank_id: null`), which means the compound could not be mapped into the TxGNN knowledge graph. Without a node in the graph, the model has no basis to generate disease associations.

This is a complex multi-ingredient formula. The components span several pharmacological classes:

- **Nitroglycerin** — a well-characterized nitric oxide donor used in cardiovascular conditions (angina pectoris)
- **Atropa belladonna** — an anticholinergic alkaloid source
- **Strychnos nux-vomica / Strychnos ignatii** — strychnine-containing seeds used in highly diluted homeopathic preparations
- **Actaea cimicifuga, Sepia officinalis** — traditionally associated with women's hormonal health in homeopathic medicine
- **Gelsemium sempervirens, Spigelia anthelmia, Bryonia alba, Iris versicolor, Sanguinaria canadensis** — homeopathic botanical components

The combination pattern is consistent with a **homeopathic compound remedy**, likely positioned for headache/migraine or menopausal symptoms, but this cannot be confirmed from the available data. Because homeopathic preparations use highly diluted substances, standard pharmacokinetic and pharmacodynamic profiling does not apply, and direct mapping to TxGNN's biomedical knowledge graph is not feasible under the current pipeline.

---

## US Market Information

No authorizations found. This product has 0 registered licenses and is not currently marketed.

---

## Safety Considerations

Please refer to the package insert for safety information.

> **Note on individual components**: While the overall product has no retrievable safety record in this dataset, some individual constituents carry known toxicity risks at non-homeopathic doses. Strychnos nux-vomica and Strychnos ignatii contain strychnine (a CNS stimulant/convulsant); Atropa belladonna contains atropine and scopolamine (anticholinergic toxidrome risk); Nitroglycerin is a potent vasodilator. If this product is being evaluated at doses above homeopathic dilution levels, a full ingredient-by-ingredient safety review is mandatory.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The TxGNN pipeline could not generate predictions for this candidate because no DrugBank ID exists, the original indications are unknown, and all safety data are absent. There is no evaluable basis for a repurposing recommendation at this stage.

**To proceed, the following is needed:**

- **Identity clarification**: Confirm whether this is a homeopathic product (in which case standard TxGNN repurposing analysis is likely not applicable) or a conventional combination drug requiring individual active ingredient mapping
- **DrugBank ID resolution**: If the product contains pharmacologically active ingredients at measurable doses, map each active component to its DrugBank node and run per-ingredient TxGNN predictions
- **Original indication documentation**: Retrieve the approved indication or intended use from the originating regulatory dossier or product label
- **MOA data**: Query DrugBank and primary literature for the mechanism of action for each active component
- **Safety profile**: Download and parse the product package insert (or equivalent regulatory document) for warnings, contraindications, and interaction data
- **Re-submission**: Once ingredient-level data is available, resubmit as separate single-ingredient or well-defined combination candidates rather than as a concatenated multi-ingredient string
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

